DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-0.12%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.54B
AUM Growth
+$4.54B
(-3.1%)
Cap. Flow
-$34.1M
Cap. Flow
% of AUM
-0.75%
Top 10 Holdings %
Top 10 Hldgs %
54.9%
Holding
116
New
14
Increased
17
Reduced
7
Closed
24
Top Buys
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$62.4M |
| 2 |
Centene
CNC
|
$44.2M |
| 3 |
Integra LifeSciences
IART
|
$43M |
| 4 |
Surgery Partners
SGRY
|
$42.7M |
| 5 |
Owens & Minor
OMI
|
$27.3M |
Top Sells
| 1 |
AMED
Amedisys
AMED
|
$164M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$36.8M |
| 3 |
NewAmsterdam Pharma
NAMS
|
$30.1M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$28.5M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 68.01% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Structure Therapeutics
GPCR
$1.14B
| $31.7M | 0.7% |
627,813
| – | – |
|
|
RYZB
27
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $25.7M | 0.57% |
+1,159,126
| New | +$25.7M |
|
28
DocGo
DCGO
$152M
| $25.4M | 0.56% |
4,764,000
+1,705,000
| +56% | +$9.09M |
|
29
BioCryst Pharmaceuticals
BCRX
$1.74B
| $23.3M | 0.51% |
3,286,000
+1,964,000
| +149% | +$13.9M |
|
30
Edgewise Therapeutics
EWTX
$1.54B
| $22.5M | 0.5% |
3,933,137
| – | – |
|
31
Insulet
PODD
$24.2B
| $20.3M | 0.45% |
+127,000
| New | +$20.3M |
|
32
Disc Medicine
IRON
$2.14B
| $20.2M | 0.45% |
430,000
| – | – |
|
33
Alignment Healthcare
ALHC
$3.23B
| $19.1M | 0.42% |
2,747,015
+905,015
| +49% | +$6.28M |
|
34
Roivant Sciences
ROIV
$8.6B
| $18.7M | 0.41% |
1,604,487
+249,513
| +18% | +$2.91M |
|
35
Caribou Biosciences
CRBU
$176M
| $16.7M | 0.37% |
+3,500,000
| New | +$16.7M |
|
36
Castle Biosciences
CSTL
$673M
| $16M | 0.35% |
+946,620
| New | +$16M |
|
37
Day One Biopharmaceuticals
DAWN
$766M
| $15.6M | 0.34% |
1,269,992
| – | – |
|
38
Viking Therapeutics
VKTX
$3.02B
| $14.2M | 0.31% |
1,279,000
+154,000
| +14% | +$1.7M |
|
39
Tarsus Pharmaceuticals
TARS
$2.44B
| $13.4M | 0.3% |
+754,042
| New | +$13.4M |
|
40
Verastem
VSTM
$585M
| $12.5M | 0.28% |
1,538,461
| – | – |
|
41
Denali Therapeutics
DNLI
$2.24B
| $12.3M | 0.27% |
594,989
| – | – |
|
42
QuidelOrtho
QDEL
$1.87B
| $11M | 0.24% |
+150,000
| New | +$11M |
|
43
Cogent Biosciences
COGT
$1.83B
| $10.6M | 0.23% |
1,089,345
-2,277,000
| -68% | -$22.2M |
|
44
Pulmonx
LUNG
$67.6M
| $10.5M | 0.23% |
1,017,958
-46,327
| -4% | -$479K |
|
|
RVNC
45
DELISTED
Revance Therapeutics, Inc.
RVNC
| $9.98M | 0.22% |
870,000
| – | – |
|
|
VIGL
46
DELISTED
Vigil Neuroscience
VIGL
| $9.85M | 0.22% |
1,827,400
-224,610
| -11% | -$1.21M |
|
|
BCYC
47
Bicycle Therapeutics
BCYC
$492M
| $9.02M | 0.2% |
+448,753
| New | +$9.02M |
|
48
Tango Therapeutics
TNGX
$745M
| $8.94M | 0.2% |
+793,729
| New | +$8.94M |
|
49
Prime Medicine
PRME
$595M
| $8.45M | 0.19% |
885,314
| – | – |
|
50
4D Molecular Therapeutics
FDMT
$302M
| $8.27M | 0.18% |
650,000
| – | – |
|